[HTML][HTML] Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
J Bordat, S Maury, M Leclerc - Frontiers in Immunology, 2023 - frontiersin.org
Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) recipients are especially
vulnerable to coronavirus disease 19 (COVID-19), because of their profound …
vulnerable to coronavirus disease 19 (COVID-19), because of their profound …
[HTML][HTML] Vaccination for seasonal flu, pneumococcal infection, and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di …
P Pedrazzoli, A Lasagna, I Cassaniti, A Piralla… - ESMO open, 2023 - Elsevier
Patients with cancer have a well-known and higher risk of vaccine-preventable diseases
(VPDs). VPDs may cause severe complications in this setting due to the immune system …
(VPDs). VPDs may cause severe complications in this setting due to the immune system …
[HTML][HTML] Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
F Angotzi, M Petrella, T Berno, G Binotto… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
The approved combination of Tixagevimab/Cilgavimab has been shown to decrease the
rate of symptomatic SARS-CoV-2 infection in patients at increased risk of inadequate …
rate of symptomatic SARS-CoV-2 infection in patients at increased risk of inadequate …
Assessing the post hoc effectiveness of tixagevimab− cilgavimab for prevention of SARS‐CoV‐2 infections in solid organ transplant recipients
Abstract Background Tixagevimab− cilgavimab (Tix‐Cil) was authorized for prophylaxis
against COVID‐19 in immunocompromised patients from December 2021 through January …
against COVID‐19 in immunocompromised patients from December 2021 through January …
[HTML][HTML] Доконтактная профилактика новой коронавирусной инфекции COVID-19 препаратом тиксагевимаб/цилгавимаб у взрослых московских пациентов с …
АА Роппельт, МС Лебедкина, АА Чернов… - Терапевтический …, 2023 - cyberleninka.ru
Обоснование. Первичные иммунодефициты (ПИД), известные на сегодняшний день
как врожденные дефекты иммунитета,-группа наследственных заболеваний …
как врожденные дефекты иммунитета,-группа наследственных заболеваний …
[HTML][HTML] Опыт применения тиксагевимаба и цилгавимаба (Эвушелд) у 86 ревматологических пациентов, получающих анти-В-клеточную терапию …
ТВ Бекетова, НО Левина, МВ Дубинская… - Научно …, 2023 - cyberleninka.ru
Проблема профилактики коронавирусной болезни 2019 (COVID-19, coronavirus disease
2019) у пациентов с иммуновоспалительными ревматическими заболеваниями (ИВРЗ) …
2019) у пациентов с иммуновоспалительными ревматическими заболеваниями (ИВРЗ) …
Wissenschaftliche Begründung der STIKO zur Aktualisierung der Empfehlung zur SARS-CoV-2-Prä-Expositionsprophylaxe mit Tixagevimab/Cilgavimab (Evusheld)
A Mikolajewska, K Kling, V Piechotta, J Koch… - 2023 - edoc.rki.de
In der im Epidemiologischen Bulletin 8/2023 veröffentlichten 25. Aktualisierung der COVID-
19-Impfempfehlung grenzt die STIKO unter Berücksichtigung der dynamischen Datenlage …
19-Impfempfehlung grenzt die STIKO unter Berücksichtigung der dynamischen Datenlage …
Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies
AA Roppelt, MS Lebedkina, AA Chernov… - Terapevticheskii …, 2023 - ter-arkhiv.ru
Background. Primary immunodeficiencies (PIDs), now known as inborn errors of immunity,
are a group of inherited diseases caused by defects in the genes that control the immune …
are a group of inherited diseases caused by defects in the genes that control the immune …
[HTML][HTML] Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review
S Alhumaid, KM Al Mutared, Z Al Alawi, Z Sabr… - Allergy, Asthma & …, 2023 - Springer
Background Inborn errors of immunity (IEIs) are considered significant challenges for
children with IEIs, their families, and their medical providers. Infections are the most common …
children with IEIs, their families, and their medical providers. Infections are the most common …
Association study between killer immunoglobulin-like receptor polymorphisms and susceptibility to COVID-19 disease: a systematic review and meta-analysis
SH Teshnizi, S Mirzazadeh, N Mashhadi, S Meri… - Immunologic …, 2024 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a known virus that leads
to a respiratory disease called coronavirus disease 19 (COVID-19). Natural killer (NK) cells …
to a respiratory disease called coronavirus disease 19 (COVID-19). Natural killer (NK) cells …